fenfluramine has been researched along with Diabetes Mellitus in 52 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "Benfluorex increases insulin sensitivity in obese type II diabetic patients." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity." | 8.75 | Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975) |
| "In the obese patients with eating disorders, the mean total caloric intake was reduced by 36%, which was highly significant." | 6.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "Benfluorex was withdrawn from European markets in June 2010 after reports of an association with heart valve lesions." | 5.38 | Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study. ( Arnalsteen, E; Boulanger, J; Donal, E; Ederhy, S; Ennezat, PV; Garban, T; Jeu, A; Jobic, Y; Maréchaux, S; Réant, P; Rusinaru, D; Tribouilloy, C, 2012) |
| "Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2." | 5.36 | Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. ( Allemand, H; Fagot, JP; Montastruc, JL; Neumann, A; Païta, M; Ricordeau, P; Simon, D; Tuppin, P; Weill, A, 2010) |
| "Fenfluramine has a lowering effect on brain serotonin, and peripheral effects on glucose and triglyceride metabolism." | 5.26 | Congenital generalized lipodystrophy and experimental lipoatrophic diabetes in rabbits treated successfully with fenfluramine. ( Foss, I; Trygstad, O, 1977) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "Dexfenfluramine aids weight loss and improves glycemic control in obese Chinese NIDDM patients over a 3- to 6-month period." | 5.08 | Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. ( Chan, JC; Chow, CC; Cockram, CS; Ko, GT; Tsang, LW; Yeung, VT, 1997) |
| "To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period." | 5.07 | Dexfenfluramine in type II diabetes: effect on weight and diabetes control. ( Davis, TM; Findlater, P; Stein, GR; Stewart, GO, 1993) |
| "Benfluorex increases insulin sensitivity in obese type II diabetic patients." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Dexfenfluramine has been shown to promote weight loss in overweight people." | 5.07 | The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. ( Molyneaux, LM; Overland, JE; Willey, KA; Yue, DK, 1992) |
| "Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity." | 4.75 | Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975) |
| " As a derivative of fenfluramine with an appetite suppressant action, benfluorex is preferentially used in overweight patients." | 3.75 | Fenfluramine-like cardiovascular side-effects of benfluorex. ( Boutet, K; Carlhant-Kowalski, D; Frachon, I; Gut-Gobert, C; Humbert, M; Jobic, Y; Leroyer, C; Simonneau, G; Sitbon, O, 2009) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "The authors have evaluated the efficacy of d-fenfluramine, a serotoninergic anorectic drug, in 42 obese patients with non-insulin-dependent diabetes mellitus (NIDDM) who not very responded only to the hypocaloric diet or associated therapy with oral hypoglycemic agents." | 3.69 | [The treatment of the obese non-insulin-dependent patient with d-fenfluramine]. ( Coco, MP; Daniele, E, 1996) |
| "To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfenfluramine in men with non-insulin dependent diabetes mellitus (NIDDM)." | 3.69 | Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. ( Clark, ML; Hockaday, TD; Marks, SJ; Moore, NR; Pointon, JJ; Ryley, NG; Strauss, BJ, 1997) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| "Dexfenfluramine was most effective in the short term, behavioural therapy useful long term but only in those who remained within the group; home visits offered no advantage." | 2.68 | The comparison of four weight reduction strategies aimed at overweight diabetic patients. ( Jung, RT; Leese, GP; Manning, RM; Newton, RW, 1995) |
| "In the obese patients with eating disorders, the mean total caloric intake was reduced by 36%, which was highly significant." | 2.68 | [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. ( Enzi, G, 1997) |
| "Benfluorex hydrochloride has known lipid- and glucose-lowering effects." | 2.67 | Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Benfluorex was withdrawn from European markets in June 2010 after reports of an association with heart valve lesions." | 1.38 | Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study. ( Arnalsteen, E; Boulanger, J; Donal, E; Ederhy, S; Ennezat, PV; Garban, T; Jeu, A; Jobic, Y; Maréchaux, S; Réant, P; Rusinaru, D; Tribouilloy, C, 2012) |
| "Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2." | 1.36 | Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. ( Allemand, H; Fagot, JP; Montastruc, JL; Neumann, A; Païta, M; Ricordeau, P; Simon, D; Tuppin, P; Weill, A, 2010) |
| "Fenfluramine has a lowering effect on brain serotonin, and peripheral effects on glucose and triglyceride metabolism." | 1.26 | Congenital generalized lipodystrophy and experimental lipoatrophic diabetes in rabbits treated successfully with fenfluramine. ( Foss, I; Trygstad, O, 1977) |
| "The problem of obesity is not well dealt with in the ordinary diabetes clinic." | 1.25 | A year's experience in a clinic for obese diabetics. ( Goldblatt, R; Jackson, WP; Movsowitz, F, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (51.92) | 18.7374 |
| 1990's | 19 (36.54) | 18.2507 |
| 2000's | 2 (3.85) | 29.6817 |
| 2010's | 4 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tribouilloy, C | 3 |
| Maréchaux, S | 2 |
| Jobic, Y | 3 |
| Jeu, A | 2 |
| Ederhy, S | 2 |
| Donal, E | 2 |
| Réant, P | 2 |
| Arnalsteen, E | 2 |
| Boulanger, J | 2 |
| Garban, T | 2 |
| Ennezat, PV | 2 |
| Andréjak, M | 2 |
| Rusinaru, D | 3 |
| Boutet, K | 1 |
| Frachon, I | 1 |
| Gut-Gobert, C | 1 |
| Leroyer, C | 1 |
| Carlhant-Kowalski, D | 1 |
| Sitbon, O | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Henon, P | 1 |
| Tribouilloy, L | 1 |
| Leleu, F | 1 |
| Sevestre, H | 1 |
| Peltier, M | 1 |
| Caus, T | 1 |
| Weill, A | 1 |
| Païta, M | 1 |
| Tuppin, P | 1 |
| Fagot, JP | 1 |
| Neumann, A | 1 |
| Simon, D | 1 |
| Ricordeau, P | 1 |
| Montastruc, JL | 1 |
| Allemand, H | 1 |
| Wade, JM | 1 |
| Juneja, P | 1 |
| MacKay, AW | 1 |
| Graham, J | 1 |
| Havel, PJ | 1 |
| Tecott, LH | 1 |
| Goulding, EH | 1 |
| Hepp, KD | 1 |
| Misra, NP | 1 |
| Bhambal, SA | 1 |
| Yesikar, SS | 1 |
| Bellani, RK | 1 |
| Manning, RM | 2 |
| Jung, RT | 2 |
| Leese, GP | 2 |
| Newton, RW | 2 |
| Khan, M | 1 |
| Lum, CT | 1 |
| Rao, V | 1 |
| Bianchi, R | 2 |
| Bongers, V | 2 |
| Bravenboer, B | 2 |
| Erkelens, DW | 2 |
| Brindley, DN | 2 |
| Stewart, GO | 1 |
| Stein, GR | 1 |
| Davis, TM | 1 |
| Findlater, P | 1 |
| Daniele, E | 1 |
| Coco, MP | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| Marks, SJ | 1 |
| Moore, NR | 1 |
| Ryley, NG | 1 |
| Clark, ML | 1 |
| Pointon, JJ | 1 |
| Strauss, BJ | 1 |
| Hockaday, TD | 1 |
| Chow, CC | 1 |
| Ko, GT | 1 |
| Tsang, LW | 1 |
| Yeung, VT | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Enzi, G | 1 |
| Nightingale, SL | 1 |
| Leutenegger, M | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 1 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Greenway, FL | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Jorgensen, KD | 1 |
| Larsen, S | 1 |
| Vejtorp, L | 1 |
| Hornnes, P | 1 |
| Bechgaard, H | 1 |
| Sestoft, L | 1 |
| Lyngsoe, J | 1 |
| Wales, JK | 1 |
| Förster, H | 1 |
| Huth, K | 1 |
| Koch, E | 1 |
| Tunali, G | 1 |
| Brumby, KH | 1 |
| Trygstad, O | 2 |
| Foss, I | 1 |
| Seip, M | 1 |
| Oseid, S | 1 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Sawyer, PR | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Asmal, AC | 1 |
| Leary, WP | 1 |
| Kesson, CM | 1 |
| Ireland, JT | 1 |
| Otim, MA | 1 |
| Jackson, WP | 1 |
| Movsowitz, F | 1 |
| Goldblatt, R | 1 |
| Sulaiman, WR | 1 |
| Johnson, RH | 1 |
| Rennie, MJ | 1 |
| Joasoo, A | 1 |
| Turtle, JR | 3 |
| Luntz, GR | 1 |
| Reuter, CJ | 1 |
| Wells, HM | 1 |
| Wilton, D | 1 |
| Riveline, B | 1 |
| Willey, KA | 1 |
| Molyneaux, LM | 1 |
| Overland, JE | 1 |
| Yue, DK | 1 |
| Balabolkin, MI | 1 |
| Novikova, OM | 1 |
| Levitskaia, ZI | 1 |
| Scheen, AJ | 1 |
| Paolisso, G | 1 |
| Salvatore, T | 1 |
| Lefèbvre, PJ | 1 |
| Burgess, JA | 1 |
| Dykes, JR | 1 |
| Wilton, TD | 1 |
| De Sereday, MS | 1 |
| Efron, HR | 1 |
| De Compte, DV | 1 |
| Raffo del Campo, MA | 1 |
| Liebermeister, H | 1 |
| Probst, G | 1 |
| Jahnke, K | 1 |
2 reviews available for fenfluramine and Diabetes Mellitus
| Article | Year |
|---|---|
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.
Topics: Adult; Age Factors; Analgesics; Anticonvulsants; Appetite Depressants; Body Temperature; Central Ner | 1975 |
22 trials available for fenfluramine and Diabetes Mellitus
| Article | Year |
|---|---|
The comparison of four weight reduction strategies aimed at overweight diabetic patients.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; | 1993 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 1993 |
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes Mellitu | 1997 |
[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Appetite Depressants; Diabetes Mellitus; Diabetes Mel | 1997 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up.
Topics: Ambulatory Care; Appetite Depressants; Diabetes Mellitus; Dietetics; Female; Fenfluramine; Follow-Up | 1998 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
Metabolic effects of fenfluramine in obese diabetics.
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Female; | 1977 |
The effect of fenfluramine on obese, maturity-onset diabetic patients.
Topics: Aged; Blood Glucose; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus; Double-Bl | 1979 |
A study of the effects of 780SE on carbohydrate tolerance and plasma hormone and lipid profile in maturity-onset diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Dietary Carbohydrates; Female; Fenfluram | 1975 |
Phenformin compared with fenfluramine in the treatment of obese diabetic patients.
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Female; Fenfluramine; Glucose Tolerance Te | 1976 |
Hormonal and metabolic studies of the action of fenfluramine in normal man, obesity, acromegaly and diabetes mellitus.
Topics: Acromegaly; Adult; Aged; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Fenfl | 1975 |
A trial of fenfluramine (PACaps) and diet in overweight diabetic patients.
Topics: Body Weight; Diabetes Mellitus; Diet, Reducing; Fenfluramine; Humans; Obesity | 1975 |
780SE in the management of disorders of lipid and glucose metabolism.
Topics: Adult; Aged; Diabetes Mellitus; Female; Fenfluramine; Humans; Hyperlipidemias; Male; Middle Aged; Ob | 1975 |
The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1992 |
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1991 |
The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics.
Topics: Adult; Aged; Diabetes Mellitus; Diet, Reducing; Fenfluramine; Glucose Tolerance Test; Humans; Insuli | 1973 |
[Hypoglycemic action of fenfluramine in obese diabetics].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Female; Fenfluramine; Humans; Hypoglycemic | 1971 |
[Experience with the appetite depressant, fenfluramine hydrochloride, in adiposity].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Child; Diabetes Mellitus; Diet, Reducing; Female; Fen | 1969 |
28 other studies available for fenfluramine and Diabetes Mellitus
| Article | Year |
|---|---|
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.
Topics: Analysis of Variance; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Diabet | 2013 |
Fenfluramine-like cardiovascular side-effects of benfluorex.
Topics: Appetite Depressants; Cardiovascular Diseases; Diabetes Mellitus; Female; Fenfluramine; Heart Valve | 2009 |
Restrictive organic mitral regurgitation associated with benfluorex therapy.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiomyopathy, Restrictive; Diabetes Mellitus; Drug Th | 2010 |
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Cohort Studies; Databases, Factual; D | 2010 |
Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.
Topics: Aged; Aortic Valve Insufficiency; Appetite Depressants; Diabetes Mellitus; Echocardiography; Europe; | 2012 |
Synergistic impairment of glucose homeostasis in ob/ob mice lacking functional serotonin 2C receptors.
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Drinking; Eating; Female; Fenfluramine; Glucose; | 2008 |
[Fenfluramine as an oral antidiabetic].
Topics: Administration, Oral; Diabetes Mellitus; Fenfluramine; Humans; Hypoglycemic Agents | 1983 |
Fenfluramine in management of obese diabetics.
Topics: Adult; Blood Pressure; Body Weight; Diabetes Mellitus; Drug Synergism; Female; Fenfluramine; Humans; | 1980 |
Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Diet, Reducing; Drug Therapy, | 1995 |
[The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
Topics: Adult; Aged; Appetite Depressants; Chronic Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr | 1996 |
Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
Topics: Adult; Biopsy; Confidence Intervals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Liver; Fema | 1997 |
From the Food and Drug Administration.
Topics: Appetite Depressants; Diabetes Mellitus; Emergency Medical Services; Fenfluramine; Heart Valve Disea | 1997 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Actions of fenfluramine on glucose uptake in vitro and in vivo.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Dogs; Drug Evaluation, Preclinical; Drug Synergism; Fatty | 1977 |
Some aspects of the physiological and pharmacological control of the synthesis of triacylglycerols and phospholipids.
Topics: Animals; Diabetes Mellitus; Energy Metabolism; Fenfluramine; Humans; Hypolipidemic Agents; Liver; Ob | 1978 |
[Is fenfluramine suitable as a therapeutic principle in obese aged diabetics? (end)].
Topics: Aged; Cholesterol; Diabetes Mellitus; Fenfluramine; Gastric Emptying; Glucose; Humans; Lactates; Obe | 1979 |
[New aspects in the management of overweight diabetics].
Topics: Diabetes Mellitus; Fenfluramine; Humans; Hypoglycemic Agents; Obesity | 1979 |
Congenital generalized lipodystrophy and experimental lipoatrophic diabetes in rabbits treated successfully with fenfluramine.
Topics: Adult; Animals; Blood Glucose; Brain; Diabetes Complications; Diabetes Mellitus; Fenfluramine; Gluco | 1977 |
Lipodystrophic diabetes treated with fenfluramine.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus; Female; Fenfluramine; Humans; Lipids; Lipodystrophy | 1977 |
Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine.
Topics: Adult; Aged; Diabetes Mellitus; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity | 1977 |
A year's experience in a clinic for obese diabetics.
Topics: Adult; Aged; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diet, Reducin | 1975 |
The action of fenfluramine in diabetes mellitus.
Topics: Diabetes Mellitus; Fenfluramine; Humans; Insulin | 1975 |
A six month study of a carbohydrate restricted diet in the management of maturity-onset diabetes and an evaluation of fenfluramine in patients unresponsive to this diet.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus; Dietary Carbohydrates; Evaluation Studies as Topic; Fem | 1975 |
Assessment of new formulation of fenfluramine in the management of the obese, diabetic African.
Topics: Adult; Africa, Southern; Blood Pressure; Body Weight; Delayed-Action Preparations; Diabetes Mellitus | 1975 |
[Effects of ponderal on the state of carbohydrate metabolism and insulin secretion in type 2 diabetes mellitus].
Topics: Adult; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; | 1991 |
Hypoglycemic action of fenfluramine in diabetes mellitus.
Topics: Adipose Tissue; Antigens; Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterifi | 1973 |
Letter: Fenfluramine in complicated obesity.
Topics: Diabetes Complications; Diabetes Mellitus; Female; Fenfluramine; Humans; Hypertension; Male; Middle | 1974 |
Current therapy of diabetes and its rationale.
Topics: Biguanides; Blood Glucose; Diabetes Mellitus; Diet Therapy; Fenfluramine; Humans; Insulin; Sulfonylu | 1971 |